TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31563241
Drug: Twice-Daily Tacrolimus
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-Daily Tacrolimus (Prograf)
Study: 31563241
Drug: Once-Daily Tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-Daily Tacrolimus (Advagraf)
Study: 31563241
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Twice-Daily and Once-Daily Tacrolimus)
Study: 28420367
Drug: iFightDepression (iFD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iFightDepression (iFD) tool + Treatment as Usual (TAU)
Study: 28420367
Drug: Internet-based psychoeducation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based psychoeducation + Treatment as Usual (TAU)
Study: 21306473
Drug: Caudal morphine-bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal morphine-bupivacaine (100 μg·kg(‐1) morphine, mixed with 0.25% bupivacaine with 1 : 200,000 epinephrine)
Study: 21306473
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (150 μg·kg(‐1)) with droperidol (75 μg·kg(‐1))
Study: 21306473
Drug: Caudal morphine-bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal morphine-bupivacaine
Study: 17881400
Drug: IVIG 150
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 150 mg/kg on Day 1, placebo on Days 2 and 3 (Group I)
Study: 17881400
Drug: IVIG 450
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 450 mg/kg on Day 1, 300 mg/kg on Day 2, 150 mg/kg on Day 3 (Group II)
Study: 17881400
Drug: IVIG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG treatment (both groups)
Study: 11558817
Drug: latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: latanoprost 0.005% once daily plus timolol 0.5% twice daily
Study: 11558817
Drug: dorzolamide 2%
Normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: dorzolamide 2% twice daily plus timolol 0.5% twice daily
Study: 9491039
Drug: Frozen solution
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frozen solution (FS)
Study: 9491039
Drug: Conventional glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glucose electrolyte solution (CS)
Study: 9491039
Drug: Frozen solution
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frozen solution (FS) after crossover from CS
Study: 9491039
Drug: Conventional glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glucose electrolyte solution (CS) after crossover from FS
Study: 3163133
Drug: High-dose cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytotoxic therapy
Study: 31748424
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia plus 7% lidocaine cream applied around the chest tube insertion site 20 min before removal (Group L)
Study: 31748424
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia plus placebo cream (Group P)
Study: 28976835
Drug: Cryopreserved human
Normalized name: cryopreserved human liver cells
DrugBank: cryopreserved human liver cells (DB05852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryopreserved human umbilical cord (cUC) allograft with negative pressure wound therapy (NPWT)
Study: 25800685
Drug: Ca/Mg infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca/Mg infusion
Study: 19293352
Drug: Lactate (Lac)
Normalized name: lactate Topical Cream [Lac-Hydrin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate (Lac) solution
Study: 19293352
Drug: Lactate/bicarbonate (Lac/Bic)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate/bicarbonate (Lac/Bic) solution
Study: 16400650
Drug: Menatetrenone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menatetrenone (45 mg daily)
Study: 15523321
Drug: Intermittent intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intravenous low-dose dobutamine therapy
Study: 9304358
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg i.v. 10 min before induction of anaesthesia (Group A)
Study: 9304358
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg i.v. 10 min before end of surgery (Group B)
Study: 9304358
Drug: Placebo at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo at both administration times (Group C)
Study: 3820443
Drug: High-dose bismuth
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose bismuth subsalicylate (2 tablets, 262 mg each, four times daily)
Study: 3820443
Drug: Low-dose bismuth
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose bismuth subsalicylate (1 tablet, 262 mg each, four times daily)
Study: 3820443
Drug: Placebo (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (four times daily)
Study: 27912106
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (BLT); details on dosage and duration not available.
Study: 9641189
Drug: Desferrioxamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desferrioxamine 0.5 mg/kg
Study: 9641189
Drug: Desferrioxamine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desferrioxamine 2.5 mg/kg
Study: 9641189
Drug: Desferrioxamine 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desferrioxamine 5.0 mg/kg
Study: 2533803
Drug: Ethanol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.5 g/kg) + Diazepam (5 mg)
Study: 2533803
Drug: Ethanol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.5 g/kg) + Meclophenoxate (100 mg)
Study: 335940
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid added to wine (10 microgram/ml)
Study: 31981604
Drug: 2.25% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.25% sodium hypochlorite gel
Study: 26678525
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg hydroxycobalamin intramuscularly
Study: 26678525
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection (placebo)
Study: 18073464
Drug: Upper extremity
Normalized name: lymphedema garments, upper extremity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upper extremity treatment protocols involving EMG‐triggered neuromuscular stimulation and coupled bilateral movements
Study: 17066490
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment plus Brief Feedback (BF)
Study: 12615581
Drug: Aminophylline 250
Normalized name: aminophylline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline 250 mg
Study: 11444269
Drug: Acitretin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (20 mg/day, two 10 mg tablets daily)
Study: 11444269
Drug: Control (tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (tablets without acitretin)
Study: 9340174
Drug: Metoprolol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (150 mg twice daily for 2 days)
Study: 9340174
Drug: Verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80 mg every 6 hours for 2 days)
Study: 9340174
Drug: Untreated patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated patients (drug free arm)
Study: 1337423
Drug: L-648,051
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-648,051
Study: 3510475
Drug: Oxacillin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxacillin (200 mg/kg/day by six bolus intravenous injections for 24 hours)
Study: 29072372
Drug: Misoprostol treatment
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol treatment (800 μg vaginally)
Study: 24423835
Drug: Hybrid intensity-modulated
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid intensity-modulated radiation therapy (IMRT) plan with flat beam open fields combined with nonflat beam IMRT fields (mixed DAO)
Study: 23430163
Drug: Tapentadol (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol (25, 50, and 75 mg)
Study: 23430163
Drug: Tramadol (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (50, 100, and 150 mg)
Study: 23430163
Drug: Hydromorphone (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (2, 4, and 6 mg)
Study: 14557363
Drug: Small resistance
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small resistance arteries with M/L ratio greater than mean (0.098) or mean +2 SD (0.11)
Study: 14557363
Drug: Small resistance
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small resistance arteries with M/L ratio less than mean (0.098) or mean +2 SD (0.11)
Study: 14557363
Drug: M/L ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: M/L ratio
Study: 3813191
Drug: Uniphyl (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniphyl (once daily at 8 P.M.)
Study: 3813191
Drug: Theo-Dur (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theo-Dur (twice daily at 8 A.M. and 8 P.M.)
Study: 24401049
Drug: Tight glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight glycemic control (target blood glucose range of 72 to 126 mg/dL)
Study: 24401049
Drug: Conventional glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glycemic control (target blood glucose level below 216 mg/dL)
Study: 18468933
Drug: Training programme
Normalized name: PUMP,LUTREPULSE PROGRAMMABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training programme (eight sessions, followed by training twice a week for 30‐45 minutes at home at the level of the ventilatory threshold [V(T)])
Study: 18468933
Drug: Usual routine
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual routine treatment
Study: 16428086
Drug: G. lucidum
Approvals — FDA: no, EMA: no, PMDA: no
Description: G. lucidum polysaccharides at 5.4 g/day for 12 weeks
Study: 14659379
Drug: Mimic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mimic therapy
Study: 1688989
Drug: Diltiazem (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60 mg three times a day for 3 days)
Study: 31484031
Drug: In-home occupational
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-home occupational therapy intervention (6 weeks)
Study: 29220347
Drug: Community-wide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-wide treatment (CWT)
Study: 29220347
Drug: School-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based treatment (SBT)
Study: 29220347
Drug: Two rounds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two rounds of treatment (with two intermittent or consecutive holiday years)
Study: 29220347
Drug: Four rounds
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four rounds of treatment (CWT or SBT)
Study: 26131911
Drug: cTACE with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: cTACE with bevacizumab (5 mg/kg every 2 weeks for 52 weeks)
Study: 23527952
Drug: hIVIG (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: hIVIG (0.5 g/kg)
Study: 23527952
Drug: VINC (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: VINC (0.02 mg/kg)
Study: 21751372
Drug: rhGH (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (2 mg/day)
Study: 16766489
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% niacinamide
Study: 11270030
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with ketamine (0.5 mg kg‐1)
Study: 8342756
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 4 ml injected through the epidural needle before catheter passage
Study: 3574424
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of isosorbide dinitrate (single dose)
Study: 3574424
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of isosorbide dinitrate (twice daily)
Study: 3574424
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of isosorbide dinitrate (three times daily)
Study: 3574424
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of isosorbide dinitrate (four times daily)
Study: 18512074
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant UFT (400 mg/day for 12 months)
Study: 16809797
Drug: Ispronicline (TC-1734)
Normalized name: Ispronicline
DrugBank: Ispronicline (DB16205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ispronicline (TC-1734) single-dose (2-320 mg)
Study: 16809797
Drug: Ispronicline (TC-1734)
Normalized name: Ispronicline
DrugBank: Ispronicline (DB16205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ispronicline (TC-1734) multiple-dose (50, 100, and 200 mg, once daily, x 10 days)
Study: 14568795
Drug: 5% PVP-I
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% PVP-I ear drops, administered topically, 3 drops 3 times daily for 10 days.
Study: 14568795
Drug: 0.3% ciprofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% ciprofloxacin ear drops, administered topically, 3 drops 3 times daily for 10 days.
Study: 8740786
Drug: Chemotherapy-treated patients
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-treated patients (excluding opposite-breast and skin tumors)
Study: 8740786
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus Tamoxifen (excluding opposite-breast and skin tumors)
Study: 1826883
Drug: Intravenous alpha-human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alpha-human ANP (initial bolus of 0.5 micrograms/kg followed by a 21-min maintenance infusion at 0.05 micrograms.kg-1.min-1)
Study: 1826883
Drug: Saline intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline intravenous infusion (control group)
Study: 7040929
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 200 mg/m2 followed by 5-fluorouracil (5-FU) 600 mg/m2
Study: 7040929
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 40 mg/m2 followed by 5-fluorouracil (5-FU) 600 mg/m2
Study: 31350870
Drug: Topical insulin-liposomal
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical insulin-liposomal gel
Study: 25044402
Drug: safinamide 50
Normalized name: safinamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: safinamide 50 mg/d
Study: 25044402
Drug: safinamide 100
Normalized name: safinamide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: safinamide 100 mg/d
Study: 20576162
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug treatment (intra-articular Sodium Hyaluronate injection)
Study: 16117450
Drug: Autologous platelet
Normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet gel (APG) application during cardiovascular surgery
Study: 12125181
Drug: Plant-derived preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant-derived preparations for symptomatic treatment of obstipation, irritable bowel, and inflammatory bowel disease
Study: 12125181
Drug: Phytotherapeutic preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytotherapeutic preparations
Study: 9924589
Drug: Trivalent oral
Normalized name: poliovirus vaccine, live, trivalent oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent oral polio vaccine (TOPV) in Group A (vaccinated at 34-35 weeks)
Study: 9924589
Drug: Trivalent oral
Normalized name: poliovirus vaccine, live, trivalent oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent oral polio vaccine (TOPV) in Group B (vaccinated at 38-40 weeks)
Study: 3338259
Drug: 1‐[3H]noradrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐[3H]noradrenaline infusion
Study: 12888589
Drug: Clarithromycin extended-release
Normalized name: Clarithromycin Extended-Release Tablets
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin extended-release formulation (1000 mg once daily for five consecutive days)
Study: 9246981
Drug: Cefuroxime (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (1.5 g single injection)
Study: 3101777
Drug: Adenosine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (intravenous boluses)
Study: 3101777
Drug: Aminophylline (antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (antagonist to adenosine)
Study: 28089225
Drug: Individualised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised treatment
Study: 26267985
Drug: High-dose ergocalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ergocalciferol (double dosage from K/DOQI recommendations)
Study: 26267985
Drug: Conventional-dose ergocalciferol
Normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional-dose ergocalciferol (as recommended by K/DOQI guidelines)
Study: 17280678
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (RSG) 8 mg/day
Study: 9270631
Drug: Prolonged regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged regimen of prophylaxis with ticarcillin/clavulanate for 2 days and low-dose vancomycin until removal of the intraaortic balloon pump (n = 28)
Study: 9270631
Drug: Prolonged regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged regimen of prophylaxis with ticarcillin/clavulanate and low-dose vancomycin (n = 28)
Study: 8175538
Drug: Inhaled furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled furosemide (45 +/- 3 mg)
Study: 8175538
Drug: Inhaled saline
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled saline (S + HV)
Study: 16517384
Drug: Augmented feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented feedback on specific biomechanical aspects of spinal manipulation therapy using an instrumented manikin
Study: 12709737
Drug: Sirolimus (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (6 mg loading dose over 48 hours plus 2 mg/day maintenance) + low-dose cyclosporine (8 mg/kg/day)
Study: 12709737
Drug: Sirolimus +
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus + low-dose cyclosporine
Study: 1518121
Drug: Panipenem/betamipron (PAPM/BP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panipenem/betamipron (PAPM/BP) administered at 10 mg/10 mg/kg
Study: 1518121
Drug: Panipenem/betamipron (PAPM/BP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panipenem/betamipron (PAPM/BP) administered at 20 mg/20 mg/kg
Study: 1518121
Drug: Panipenem/betamipron (PAPM/BP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panipenem/betamipron (PAPM/BP) administered at 31.3 mg/31.3 mg/kg
Study: 1518121
Drug: Panipenem/betamipron (PAPM/BP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panipenem/betamipron (PAPM/BP) administered in various doses (5.2 mg/5.2 mg to 31.3 mg/31.3 mg/kg)
Study: 19033604
Drug: Tango dance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tango dance program (10 weeks, 40 hours, 2 hours twice a week)
Study: 19033604
Drug: Walking program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walking program (10 weeks, 40 hours, 2 hours twice a week)
Study: 7585841
Drug: ICI 204,636
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 204,636 (25 to 250 mg/d)
Study: 2186067
Drug: Thermal biofeedback
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal biofeedback with adjunctive relaxation training (TBF)
Study: 2186067
Drug: Thermal biofeedback
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal biofeedback plus cognitive therapy
Study: 657994
Drug: Tinidazole (55.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (55.5 mg/kg)
Study: 657994
Drug: Metronidazole (52.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (52.0 mg/kg)
Study: 31394314
Drug: Bouncing Image
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bouncing Image Training Task (BITT) - daily sessions for one week
Study: 16939559
Drug: Sequential reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential reduction scenarios
Study: 10960626
Drug: Estrogen 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen 0.625 mg/day
Study: 6599665
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (continue medication)
Study: 21090831
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg once daily for a median follow-up of 1.9 years
Study: 10575333
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg/day p.o. plus standard therapy
Study: 1907675
Drug: 22.5% BCAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22.5% BCAA solution
Study: 6125625
Drug: Beta-receptor blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-receptor blocker (10 mg of bunitrolol)